Combination Therapy of Atezolizumab and Bevacizumab

Patients received a combination therapy of atezolizumab and bevacizumab (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) via intravenous administration. The dosage consisted of 1200 mg of atezolizumab and 15 mg/kg of bevacizumab, given every 3 weeks until either tumor progression or unacceptable adverse events occurred. If clinical benefits were observed, treatment was continued even beyond tumor progression. In the event of adverse events, patients were allowed to receive monotherapy of either atezolizumab or bevacizumab, depending on the type of adverse event experienced.